Ítem
Acceso Abierto

Incidence and risk of xerosis with targeted anticancer therapies

Mostrar el registro sencillo de la publicación
dc.creatorValentine, Johannahspa
dc.creatorBelum, Viswanath Reddyspa
dc.creatorDuran, Juanitaspa
dc.creatorCiccolini, Kathrynspa
dc.creatorSchindler, Katjaspa
dc.creatorWu, Shenhongspa
dc.creatorLacouture, Mario E.spa
dc.date.accessioned2020-05-25T23:56:36Z
dc.date.available2020-05-25T23:56:36Z
dc.date.created2015spa
dc.description.abstractBackground Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. Objective We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs. Methods The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models. Results The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P less than .001). Limitations The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions. Conclusion Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.jaad.2014.12.010
dc.identifier.issn10976787
dc.identifier.issn01909622
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22471
dc.language.isoengspa
dc.publisherMosby Inc.spa
dc.relation.citationEndPage667
dc.relation.citationIssueNo. 4
dc.relation.citationStartPage656
dc.relation.citationTitleJournal of the American Academy of Dermatology
dc.relation.citationVolumeVol. 72
dc.relation.ispartofJournal of the American Academy of Dermatology, ISSN:10976787, 01909622, Vol.72, No.4 (2015); pp. 656-667spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84929516117&doi=10.1016%2fj.jaad.2014.12.010&partnerID=40&md5=f0bc4fba52840076f8dcb287fcb8382dspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAfatinibspa
dc.subject.keywordphase ii as topiceng
dc.subject.keywordAlitretinoinspa
dc.subject.keywordAnastrozolespa
dc.subject.keywordAntineoplastic agentspa
dc.subject.keywordAxitinibspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordBexarotenespa
dc.subject.keywordBortezomibspa
dc.subject.keywordBosutinibspa
dc.subject.keywordBrentuximab vedotinspa
dc.subject.keywordCabozantinibspa
dc.subject.keywordCarfilzomibspa
dc.subject.keywordCeritinibspa
dc.subject.keywordCetuximabspa
dc.subject.keywordCrizotinibspa
dc.subject.keywordDabrafenibspa
dc.subject.keywordDaclizumabspa
dc.subject.keywordDasatinibspa
dc.subject.keywordDenileukin diftitoxspa
dc.subject.keywordDenosumabspa
dc.subject.keywordErlotinibspa
dc.subject.keywordEverolimusspa
dc.subject.keywordExemestanespa
dc.subject.keywordFulvestrantspa
dc.subject.keywordGefitinibspa
dc.subject.keywordIbritumomab tiuxetanspa
dc.subject.keywordIbrutinibspa
dc.subject.keywordTrastuzumab emtansinespa
dc.subject.keywordUnindexed drugspa
dc.subject.keywordAntineoplastic agentspa
dc.subject.keywordAntineoplastic hormone agonists and antagonistsspa
dc.subject.keywordEnzyme inhibitorspa
dc.subject.keywordHormone antagonistspa
dc.subject.keywordMonoclonal antibodyspa
dc.subject.keywordTumor proteinspa
dc.subject.keywordAge distributionspa
dc.subject.keywordArticlespa
dc.subject.keywordCancer chemotherapyspa
dc.subject.keywordCancer patientspa
dc.subject.keywordCancer registryspa
dc.subject.keywordControlled clinical trial (topic)spa
dc.subject.keywordDermatologistspa
dc.subject.keywordDrug therapyspa
dc.subject.keywordHigh risk patientspa
dc.subject.keywordHumanspa
dc.subject.keywordIncidencespa
dc.subject.keywordMedical societyspa
dc.subject.keywordMedlinespa
dc.subject.keywordMolecularly targeted therapyspa
dc.subject.keywordNeoplasmspa
dc.subject.keywordPhase 1 clinical trial (topic)spa
dc.subject.keywordPhase 2 clinical trial (topic)spa
dc.subject.keywordPhase 3 clinical trial (topic)spa
dc.subject.keywordPriority journalspa
dc.subject.keywordRandomized controlled trial (topic)spa
dc.subject.keywordRisk factorspa
dc.subject.keywordSkin manifestationspa
dc.subject.keywordSystematic reviewspa
dc.subject.keywordWeb of sciencespa
dc.subject.keywordXerosisspa
dc.subject.keywordAdverse effectsspa
dc.subject.keywordAntagonists and inhibitorsspa
dc.subject.keywordChemically inducedspa
dc.subject.keywordComplicationspa
dc.subject.keywordMeta analysisspa
dc.subject.keywordMolecularly targeted therapyspa
dc.subject.keywordNeoplasmsspa
dc.subject.keywordProspective studyspa
dc.subject.keywordRiskspa
dc.subject.keywordSeverity of illness indexspa
dc.subject.keywordSkin diseasesspa
dc.subject.keywordAntibodieseng
dc.subject.keywordAntineoplastic agentsspa
dc.subject.keywordAntineoplastic agentseng
dc.subject.keywordClinical trialseng
dc.subject.keywordClinical trialseng
dc.subject.keywordEnzyme inhibitorsspa
dc.subject.keywordHormone antagonistsspa
dc.subject.keywordHumansspa
dc.subject.keywordIncidencespa
dc.subject.keywordMolecular targeted therapyspa
dc.subject.keywordNeoplasm proteinsspa
dc.subject.keywordNeoplasmsspa
dc.subject.keywordProspective studiesspa
dc.subject.keywordRiskspa
dc.subject.keywordSeverity of illness indexspa
dc.subject.keywordSkin diseasesspa
dc.subject.keywordCd20spa
dc.subject.keywordCd52spa
dc.subject.keywordDry skinspa
dc.subject.keywordEgfrspa
dc.subject.keywordHdacspa
dc.subject.keywordHer2spa
dc.subject.keywordIncidencespa
dc.subject.keywordKey words bcr-ablspa
dc.subject.keywordMekspa
dc.subject.keywordMtorspa
dc.subject.keywordRafspa
dc.subject.keywordRiskspa
dc.subject.keywordVegfrspa
dc.subject.keywordXerosisspa
dc.titleIncidence and risk of xerosis with targeted anticancer therapiesspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
1-s2-0-S0190962214022701-main.pdf
Tamaño:
1.48 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos